As such, there is great interest in FXR as a therapeutic target for treating chronic liver diseases, including cholestasis, cirrhosis, and nonalcoholic steatohepatitis (NASH) (3, 4, 18). Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.